Scoping review finds inconsistent diagnostic basis for 'neurodivergent' label
A scoping review of 134 studies (151,134 participants) examined how the terms neurodivergence and neurodiversity are used in mental health research. Participants were most often identified via self-reported diagnosis (41.8%) or self-identification (37.3%) rather than clinical assessment, and the diagnoses most commonly associated with these terms were autism (68.7%), ADHD (64.2%), dyslexia (32.8%), dyspraxia (15.7%), anxiety disorder (14.9%), and dyscalculia (12.7%); 21.6% of studies specified no clinical diagnosis at all. The authors concluded that the terms' lack of specificity introduces heterogeneity into research on clinically defined conditions and suggest prioritizing precise diagnostic descriptors in clinical and research contexts, reserving neurodivergent language for studies focused on self-identification and identity.
Most relevant for: Researchers and clinicians involved in studies or services concerning autism, ADHD, dyslexia, dyspraxia, dyscalculia, or other conditions labeled as neurodivergent.
Read the original at JAMA PsychiatrySummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More psychiatry updates
- Caring Letters Not Linked to Lower Suicide Mortality in VeteransOct 14, 2026
- US benzodiazepine dispensing fell 26.7% from 2013 to 2024Sep 30, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 1 mL, Delivers: 10 mL, Oral Elixir, PAI, Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 10 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 10 mg per 2 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026